Reduction of Complements C₃ and C₄ in Saliva and Serum of Patients Suffering SARS-CoV-2 Infection

Nima Rahimi Petrudi, Iraj Mirzaii-Dizgah, Ali Atashabparvar, and Seyyed-Javad Hosseini-Shokouh

1Department of Physiology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
2Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran
3Department of Pathology, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

Corresponding author: Department of Physiology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran. Email: emirzaii@alumnus.tums.ac.ir

Received 2023 November 15; Revised 2023 December 04; Accepted 2023 December 04.

Abstract

Background: The complement system plays a role in chronic immune activation during viral infections.
Objectives: This study aimed to evaluate the levels of saliva and serum complements C₃ and C₄ in coronavirus disease 2019 (COVID-19) patients and healthy individuals.
Methods: This cross-sectional study included 36 severe and 22 critical COVID-19 hospitalized patients and 22 healthy individuals. Serum and unstimulated salivary C₃ and C₄ levels were assessed using the immunoturbidimetric method and analyzed using one-way analysis of variance (ANOVA) with the Student-Newman-Keuls test as a post hoc analysis.
Results: Salivary C₃ and C₄ levels were significantly lower in patients with severe and critical COVID-19 than in healthy individuals. There was no significant difference between the groups infected with severe and critical COVID-19. Serum C₃ and C₄ levels were lower in critical COVID-19 patients than in healthy individuals; nevertheless, no significant difference was observed between severe COVID-19 patients and healthy individuals. Additionally, serum C₄ levels were lower in critical COVID-19 patients than in severe COVID-19 patients.
Conclusions: It appears that serum and salivary C₃ and C₄ levels decrease in patients with COVID-19 infection.

Keywords: Complement Proteins, Saliva, Serum, COVID-19

1. Background

The coronavirus disease 2019 (COVID-19) remains a global concern and continues to claim victims. In severe cases, as with other serious illnesses, there is evidence of changes in serum complement levels (1). Respiratory deterioration in this disease has been associated with increased viral loads and an inadequate immune response (2). The complement system plays a crucial role in preventing various infectious strains by activating both the innate and acquired immune systems (3). It comprises several proteins, and the activity of each pathway ultimately leads to the cleavage and conversion of complement components, such as complement C₃ (4). There is controversy surrounding the role of the complement system in COVID-19. Some studies have shown an increase in complement levels (5); however, others have demonstrated a decrease (6, 7), and some reports have indicated no changes (8).

The activation of C₃ exacerbates disease severity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated acute respiratory distress syndrome (ARDS). C₃-deficient mice infected with SARS-CoV-2 exhibited almost normal respiratory function. These mice had fewer neutrophils and inflammatory monocytes infiltrating the lung tissue, resulting in lower levels of cytokines and chemokines in the lungs and serum (9).

Complement activity increases in hospitalized COVID-19 patients and is significantly associated with markers of inflammation. Patients with lower C₃ levels and high complement activity had a higher mortality rate than those with normal complement activity and C₃ levels (7).

Saliva has been used for years to assess human health and diseases (10-17), offering numerous advantages as a non-invasive, painless, safe, and easily accessible sample.
Its sampling can be repeated comfortably.

2. Objectives

This study aimed to evaluate the levels of C₃ and C₄ in both saliva and serum of patients with severe and critical COVID-19 and healthy individuals. The goal was to determine whether COVID-19 infection affects the levels of C₃ and C₄ in both saliva and serum.

3. Methods

A cross-sectional study was conducted at Shahid Mohammadi Hospital in Bandar Abbas, Iran. The study was approved by the Ethics Committee of AJA University of Medical Sciences, Tehran, Iran (IR.AJAUMS.REC.1401.116). This prospective monocentric study included a total of 58 patients. There were 22 patients in the critical stage (mean age: 40.2 ± 10.9 years) and 36 patients in the severe stage (mean age: 44.3 ± 13.3 years) who were admitted to the COVID-19 unit.

The control group consisted of 22 individuals (mean age: 40.1 ± 5.5 years), including 9 males and 13 females, who were selected from healthcare workers undergoing annual occupational health assessments. Participants who were less than 18 years old and had autoimmune diseases, such as systemic lupus erythematosus, autoimmune liver disease, and Sjögren’s syndrome, were excluded from the study. All relevant background information was evaluated and recorded at the time of admission (Table 1). The mean ± standard deviation (SD) ages were 40.1 ± 5.5 years for healthy individuals, 40.2 ± 10.9 years for those with severe COVID-19 infection, and 44.3 ± 13.3 years for those in critical condition.

Table 1. Demographic Characteristics of Study Patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>Severe COVID-19</th>
<th>Critical COVID-19</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (female/male)</td>
<td>14/22</td>
<td>13/9</td>
<td>0.134</td>
</tr>
<tr>
<td>Red blood cell (per µL)</td>
<td>4935500 ± 85180</td>
<td>4973600 ± 157950</td>
<td>0.817</td>
</tr>
<tr>
<td>White blood cell (per µL)</td>
<td>5050 ± 347</td>
<td>7360 ± 909</td>
<td>0.005</td>
</tr>
<tr>
<td>Neutrophil (%)</td>
<td>69.7 ± 1.9</td>
<td>74.4 ± 1.2</td>
<td>0.195</td>
</tr>
<tr>
<td>Lymphocyte (%)</td>
<td>25.0 ± 1.7</td>
<td>21.0 ± 2.6</td>
<td>0.202</td>
</tr>
<tr>
<td>Neutrophil/lymphocyte ratio</td>
<td>3.94 ± 0.47</td>
<td>5.32 ± 0.84</td>
<td>0.128</td>
</tr>
</tbody>
</table>


Serum and whole saliva samples were collected from participants between 9 and 11 a.m. The participants were advised not to eat, drink, or smoke for at least 2 hours before sample collection. The patients were instructed to sit comfortably and spit saliva into a plastic falcon tube using a funnel. On the morning of saliva collection, 2 mL of venous blood was collected from all participants and placed in gel clot tubes. The samples were then centrifuged at 3000 rpm for 10 minutes. The supernatants from both saliva and serum samples were stored at -70°C. After the completion of sample collection, all samples were thawed and sent to the laboratory for the determination of serum and salivary levels of C₃ and C₄ proteins using the immunoturbidimetric method (Biorexfars, Shiraz, Iran), following the manufacturer's instructions.

3.1. Statistical Analysis

The data are presented as mean ± standard error of the mean (SEM) and were analyzed using one-way analysis of variance (ANOVA), followed by the Student-Newman-Keuls test as a post hoc analysis.

4. Results

Significant differences in the mean levels of saliva C₃ and C₄ were observed among the groups (Table 2). Saliva C₃ and C₄ levels were lower in patients with severe and critical COVID-19 than in healthy individuals. However, there was no significant difference between patients with severe and critical COVID-19. Similarly, significant differences in the mean levels of serum C₃ and C₄ were observed among the groups (Table 2). Serum C₃ levels were lower in critical COVID-19 patients than in healthy individuals, with no significant difference between severe COVID-19 patients and healthy individuals. Serum C₄ levels were lower in critical COVID-19 patients than in both healthy individuals and severe COVID-19-infected groups; nevertheless, there was no significant difference between severe COVID-19 patients and healthy individuals.

5. Discussion

Severe acute respiratory syndrome coronavirus 2 might infect the salivary glands, potentially affecting saliva composition. In this study, the levels of C₃ and C₄ in the serum and saliva of healthy individuals and patients with severe and critical COVID-19 were evaluated. The results demonstrated that the levels of C₃ and C₄ in patients’ saliva were significantly lower than those in the healthy participants. Furthermore, the serum levels of C₃ and C₄ were lower in individuals with critical COVID-19.
infection than in healthy individuals. Additionally, serum C₄ levels were lower in individuals with critical COVID-19 infection than in those with severe COVID-19 infection. However, there was no significant difference in serum C₃ and C₄ levels between individuals with severe COVID-19 infection and healthy individuals.

The innate immune system plays a pivotal role in responding to viral infections. Previous studies have shown that the complement system significantly contributes to immune activation in patients with human immunodeficiency virus (HIV). In sepsis, the virus primarily activates the complement system through the classical pathway, leading to increased C₄ consumption (18). Similarly, complement activation occurs during COVID-19 infection (19). Several reports have indicated a reduction in serum C₃ and C₄ levels in SARS-CoV-2-infected patients (1, 20-22). It has also been reported that serum C₃ and C₄ levels are reduced in other viral diseases, such as hepatitis B (23). It has been reported that C₃ significantly correlates with inflammatory markers, such as white blood cell count, C-reactive protein, ferritin, D-dimer, and albumin. Therefore, with higher COVID-19 severity, there is a decrease in the concentrations of C₃ and C₄, likely due to complement activation and an increase in mortality (24). These results align with the results of the present study, although there is an opposing report suggesting higher levels of complement components C₃ and C₄ than normal ranges in COVID-19 patients (5).

The current study revealed reduced salivary levels of C₃ and C₄ in both severe and critical SARS-CoV-2 infections. To the best of our knowledge, there have been no previous reports on C₃ and C₄ levels in the saliva of SARS-CoV-2-infected patients. The amount of C₃ and C₄ in the serum of the severe SARS-CoV-2 infections group did not decrease significantly; however, a significant decrease was observed in the saliva of these patients. Importantly, the reduction of these complements in the saliva of these patients appears to occur earlier than in the serum, suggesting that the virus might initially affect

The following table provides the serum and saliva levels of C₃ and C₄ in Coronavirus Disease 2019 (COVID-19) patients. The data are expressed as mean ± SEM and analyzed by one-way ANOVA and Student-Newman-Keuls as post hoc tests.

### Table 2. Serum and Saliva Levels of C₃ and C₄ in Coronavirus Disease 2019 Infection

<table>
<thead>
<tr>
<th>Variables</th>
<th>Control</th>
<th>Severe COVID-19</th>
<th>Critical COVID-19</th>
<th>F</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saliva C₃ (mg/dL)</td>
<td>0.22 ± 0.06</td>
<td>0.08 ± 0.02 b</td>
<td>0.08 ± 0.02 b</td>
<td>5.150</td>
<td>0.008</td>
</tr>
<tr>
<td>Saliva C₄ (mg/dL)</td>
<td>0.07 ± 0.04</td>
<td>0.02 ± 0.01 b</td>
<td>0.02 ± 0.01 b</td>
<td>4.371</td>
<td>0.039</td>
</tr>
<tr>
<td>Serum C₃ (mg/dL)</td>
<td>132.3 ± 5.3</td>
<td>120.6 ± 4.3</td>
<td>104.3 ± 10.1 b</td>
<td>5.85</td>
<td>0.014</td>
</tr>
<tr>
<td>Serum C₄ (mg/dL)</td>
<td>31.9 ± 1.7</td>
<td>29.2 ± 1.9</td>
<td>21.8 ± 2.8 b, c</td>
<td>3.964</td>
<td>0.024</td>
</tr>
</tbody>
</table>

Abbreviations: COVID-19, coronavirus disease 2019; SEM, standard error of the mean; ANOVA, analysis of variance.

* The data are expressed as mean ± SEM and analyzed by one-way ANOVA and Student-Newman-Keuls as post hoc tests.

b P < 0.05 in comparison to the control group.

P < 0.05 in comparison to severe COVID-19 infected group.

### 5.1. Conclusions

It appears that both serum and salivary C₃ and C₄ levels decrease in patients with COVID-19 infection.

### Footnotes

**Authors' Contribution:** Conception, design, and supervision, and data analysis: Iraj Mirzali-Dizgah; drafting of the manuscript: Nima Rahimi Petrudi, Ali Atashabparvar, and Seyed-Javad Hosseini-Shokouh; administrative, technical support: Ali Atashabparvar and Seyed-Javad Hosseini-Shokouh.

**Conflict of Interests:** The authors declare that they have no conflict of interest.

**Ethical Approval:** The Ethics Committee of AJA University of Medical Sciences (IR.AJAUMS.REC.1401.116) approved the present study.

**Funding/Support:** There was no funding/support.

### References


